Literature DB >> 14575801

Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine.

Pierre Paul Van Bogaert1, François Pittoors.   

Abstract

The action of the bradycardiac agents, cilobradine (DK-AH269) and zatebradine (UL-FS49), on the cardiac pacemaker current (If) was investigated on short Purkinje fibres from sheep hearts, using the two-microelectrode voltage-clamp technique, and on isolated rabbit sino-atrial cells with the patch clamp technique. These drugs reduce dose dependently the amplitude of the If, without modifying either the voltage dependence or the kinetics of channel activation. When voltage-clamp pulse trains were applied, cilobradine induced a use-dependent blockade of If that was stronger and faster than that with zatebradine. Recovery from blockade during prolonged hyperpolarization was significantly faster with zatebradine. Presumably, both drugs block the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel by gaining access to a binding site within the open channel pore, and are removed from the blocking site by strong hyperpolarization with large inward If through the open channel. Cilobradine, compared to zatebradine blocks If more effectively and faster in both preparations. Consequently cilobradine strongly reduces the pacemaker diastolic depolarization rate and the cell's firing frequency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575801     DOI: 10.1016/j.ejphar.2003.08.083

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  HCN2 channels: a permanent open state and conductance changes.

Authors:  François Pittoors; Pierre Paul Van Bogaert
Journal:  J Membr Biol       Date:  2014-11-13       Impact factor: 1.843

2.  State-dependent contribution of the hyperpolarization-activated Na+/K+ and persistent Na+ currents to respiratory rhythmogenesis in vivo.

Authors:  Gaspard Montandon; Richard L Horner
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

Review 3.  Cellular mechanisms underlying the pharmacological induction of phosphenes.

Authors:  L Cervetto; G C Demontis; C Gargini
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

4.  Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.

Authors:  C Thollon; S Bedut; N Villeneuve; F Cogé; L Piffard; J-P Guillaumin; C Brunel-Jacquemin; P Chomarat; J-A Boutin; J-L Peglion; J-P Vilaine
Journal:  Br J Pharmacol       Date:  2006-11-27       Impact factor: 8.739

Review 5.  The pharmacology of cyclic nucleotide-gated channels: emerging from the darkness.

Authors:  R Lane Brown; Timothy Strassmaier; James D Brady; Jeffrey W Karpen
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  Joint population pharmacokinetic/pharmacodynamic model for the heart rate effects at rest and at the end of exercise for cilobradine.

Authors:  Nieves Vélez de Mendizábal; Alexander Staab; Hans Günter Schäfer; Dirk Trommeshauser; Christiane Döge; Matthias Klüglich; Juliet Roberts; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2012-12-11       Impact factor: 4.200

7.  Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.

Authors:  A Bucchi; A Tognati; R Milanesi; M Baruscotti; D DiFrancesco
Journal:  J Physiol       Date:  2006-02-16       Impact factor: 5.182

Review 8.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.

Authors:  Gabriele Fliss; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans G Schaefer; Charlotte Kloft
Journal:  Pharm Res       Date:  2007-06-21       Impact factor: 4.200

Review 10.  Cardiac cAMP: production, hydrolysis, modulation and detection.

Authors:  Cédric Boularan; Céline Gales
Journal:  Front Pharmacol       Date:  2015-10-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.